Clinical trial
An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
NCT07506668 is registered in ClinicalTrials.gov with Affiliated Hospital of Nantong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
- Lead sponsor
- Affiliated Hospital of Nantong University
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- March 23, 2026
- Completion date
- May 30, 2028
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed/refractory b-cell lymphoma